Emergent BioSolutions (EBS) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Emergent BioSolutions Revenue Highlights

Latest Revenue (Y)

$1.05B

Latest Revenue (Q)

$254.70M

Main Segment (Y)

Product

Main Geography (Y)

Services Segment

Emergent BioSolutions Revenue by Period

Emergent BioSolutions Revenue by Year

Date	Revenue	Change
2023-12-31	$1.05B	-6.39%
2022-12-31	$1.12B	-37.47%
2021-12-31	$1.79B	15.26%
2020-12-31	$1.56B	40.63%
2019-12-31	$1.11B	41.36%
2018-12-31	$782.40M	39.50%
2017-12-31	$560.87M	14.75%
2016-12-31	$488.78M	-6.50%
2015-12-31	$522.79M	16.14%
2014-12-31	$450.14M	43.93%
2013-12-31	$312.75M	10.95%
2012-12-31	$281.89M	3.11%
2011-12-31	$273.38M	-4.47%
2010-12-31	$286.17M	21.89%
2009-12-31	$234.79M	31.49%
2008-12-31	$178.55M	-2.38%
2007-12-31	$182.91M	19.76%
2006-12-31	$152.73M	16.87%
2005-12-31	$130.69M	56.52%
2004-12-31	$83.49M	49.71%
2003-12-31	$55.77M	-28.99%
2002-12-31	$78.54M	73.35%
2001-12-31	$45.31M	-

Emergent BioSolutions generated $1.05B in revenue during NA 2023, up -6.39% compared to the previous quarter, and up 134.11% compared to the same period a year ago.

Emergent BioSolutions Revenue by Quarter

Date	Revenue	Change
2024-06-30	$254.70M	-15.21%
2024-03-31	$300.40M	8.60%
2023-12-31	$276.60M	2.26%
2023-09-30	$270.50M	-19.95%
2023-06-30	$337.90M	104.66%
2023-03-31	$165.10M	-50.08%
2022-12-31	$330.70M	37.79%
2022-09-30	$240.00M	-1.11%
2022-06-30	$242.70M	-21.07%
2022-03-31	$307.50M	-57.48%
2021-12-31	$723.20M	119.82%
2021-09-30	$329.00M	-17.23%
2021-06-30	$397.50M	15.89%
2021-03-31	$343.00M	-41.17%
2020-12-31	$583.00M	51.35%
2020-09-30	$385.20M	-2.41%
2020-06-30	$394.70M	105.04%
2020-03-31	$192.50M	-46.59%
2019-12-31	$360.40M	15.59%
2019-09-30	$311.80M	28.21%
2019-06-30	$243.20M	27.60%
2019-03-31	$190.60M	-29.59%
2018-12-31	$270.70M	55.89%
2018-09-30	$173.65M	-21.14%
2018-06-30	$220.20M	86.90%
2018-03-31	$117.81M	-39.21%
2017-12-31	$193.81M	29.70%
2017-09-30	$149.43M	48.29%
2017-06-30	$100.77M	-13.77%
2017-03-31	$116.86M	-22.95%
2016-12-31	$151.66M	6.12%
2016-09-30	$142.91M	40.82%
2016-06-30	$101.49M	-8.57%
2016-03-31	$111.00M	-33.97%
2015-12-31	$168.10M	1.92%
2015-09-30	$164.94M	30.79%
2015-06-30	$126.11M	98.19%
2015-03-31	$63.63M	-57.00%
2014-12-31	$147.97M	7.26%
2014-09-30	$137.95M	25.04%
2014-06-30	$110.33M	104.75%
2014-03-31	$53.88M	-45.08%
2013-12-31	$98.11M	10.11%
2013-09-30	$89.10M	8.09%
2013-06-30	$82.44M	91.27%
2013-03-31	$43.10M	-54.44%
2012-12-31	$94.61M	42.07%
2012-09-30	$66.59M	-5.38%
2012-06-30	$70.38M	39.89%
2012-03-31	$50.31M	-53.39%
2011-12-31	$107.95M	83.70%
2011-09-30	$58.76M	-33.33%
2011-06-30	$88.14M	375.59%
2011-03-31	$18.53M	-82.05%
2010-12-31	$103.25M	39.55%
2010-09-30	$73.99M	19.07%
2010-06-30	$62.14M	32.77%
2010-03-31	$46.80M	-13.02%
2009-12-31	$53.80M	24.34%
2009-09-30	$43.27M	-40.88%
2009-06-30	$73.19M	13.44%
2009-03-31	$64.52M	80.47%
2008-12-31	$35.75M	-36.84%
2008-09-30	$56.60M	30.16%
2008-06-30	$43.48M	1.79%
2008-03-31	$42.72M	-52.34%
2007-12-31	$89.64M	-

Emergent BioSolutions generated $254.70M in revenue during Q2 2024, up -15.21% compared to the previous quarter, and up 154.27% compared to the same period a year ago.

Emergent BioSolutions Revenue Breakdown

Emergent BioSolutions Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Commercial Product	$497.30M	-	-	-	-
Product	$944.50M	$966.20M	-	-	-
Contracts and Grants	$26.30M	$41.40M	$71.30M	-	-
Service	$72.80M	-	-	-	-
Contract Development And Manufacturing	-	$113.30M	$450.50M	$80.00M	-
Contract Development And Manufacturing, Leases	-	-	$108.00M	-	-
Contracted Operating Leases	-	-	-	$165.30M	-

Emergent BioSolutions's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (61.30%), Commercial Product (32.27%), Service (4.72%), and Contracts and Grants (1.71%).

Quarterly Revenue by Product

Product/Service	Sep 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Sep 21	Jun 21	Mar 21	Sep 20
Contracts and Grants	$10.00M	$6.70M	$6.50M	$6.60M	$6.50M	$7.10M	$17.40M	$7.30M	$9.60M	-	-	-	-
Service	$13.90M	$59.60M	$13.20M	-	-	$17.70M	-	-	-	-	-	-	-
Product	$269.50M	$249.10M	$249.80M	$302.20M	$143.40M	$305.70M	-	-	-	-	-	-	-
Commercial Product	$95.30M	-	-	-	-	-	-	-	-	-	-	-	-
Contract Development And Manufacturing	-	-	$14.20M	$29.10M	$15.20M	$17.90M	-	-	-	-	-	-	-
Contract Development And Manufacturing, Leases	-	-	-	-	-	-	$200.00K	$400.00K	$104.20M	$114.60M	-	-	-
Contracted Operating Leases	-	-	-	-	-	-	-	-	-	-	$129.70M	$146.60M	$177.70M

Emergent BioSolutions's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (69.33%), Commercial Product (24.52%), Service (3.58%), and Contracts and Grants (2.57%).

Emergent BioSolutions Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Services Segment	$78.50M	-	-	-	-
CANADA	-	$148.60M	-	-	-
UNITED STATES	-	$889.50M	$897.80M	$626.00M	$568.80M
Other Geographical Area	-	$82.80M	-	-	-
Non-US	-	-	$894.90M	$363.80M	$334.70M

Emergent BioSolutions's latest annual revenue breakdown by geography, as of Dec 23: Services Segment (100.00%).

Quarterly Revenue by Country

Country	Sep 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
Services Segment	$14.30M	$20.00M	$14.20M	$29.10M	$15.20M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
UNITED STATES	-	-	-	-	-	$602.80M	$49.80M	$124.40M	$112.50M	$502.60M	$60.20M	$66.30M	$56.40M	$235.50M	$102.40M	$224.20M	$63.90M	$230.70M	$170.20M	$94.60M
Non-US	-	-	-	-	-	-	$190.20M	$118.30M	$195.00M	$220.60M	$268.80M	$114.90M	$81.50M	$105.40M	$99.80M	$74.30M	$84.30M	$80.10M	$86.00M	$88.90M

Emergent BioSolutions's latest quarterly revenue breakdown by geography, as of Sep 24: Services Segment (100.00%).

Emergent BioSolutions Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
BHC	Bausch Health Companies	$8.76B	$2.51B
ZTS	Zoetis	$8.54B	$2.39B
NBIX	Neurocrine Biosciences	$1.89B	$622.10M
ALKS	Alkermes	$1.66B	$378.14M
PBH	Prestige Consumer Healthcare	$1.13B	$283.55M
EBS	Emergent BioSolutions	$1.05B	$254.70M
COLL	Collegium Pharmaceutical	$566.77M	$159.30M
ITCI	Intra-Cellular Therapies	$462.18M	$175.38M
LFCR	Lifecore Biomedical	$128.26M	$24.70M
CPIX	Cumberland Pharmaceuticals	$39.55M	$9.09M
DRRX	DURECT	$8.55M	$1.56M
AKAN	Akanda	$2.16M	$762.61K

EBS Revenue FAQ

What is Emergent BioSolutions’s yearly revenue?

Emergent BioSolutions's yearly revenue for 2023 was $1.05B, representing a decrease of -6.39% compared to 2022. The company's yearly revenue for 2022 was $1.12B, representing a decrease of -37.47% compared to 2021. EBS's yearly revenue for 2021 was $1.79B, representing an increase of 15.26% compared to 2020.

What is Emergent BioSolutions’s quarterly revenue?

Emergent BioSolutions's quarterly revenue for Q2 2024 was $254.7M, a -15.21% decrease from the previous quarter (Q1 2024), and a -24.62% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $300.4M, a 8.60% increase from the previous quarter (Q4 2023), and a 81.95% increase year-over-year (Q1 2023). EBS's quarterly revenue for Q4 2023 was $276.6M, a 2.26% increase from the previous quarter (Q3 2023), and a -16.36% decrease year-over-year (Q4 2022).

What is Emergent BioSolutions’s revenue growth rate?

Emergent BioSolutions's revenue growth rate for the last 3 years (2021-2023) was -41.47%, and for the last 5 years (2019-2023) was -5.13%.

What are Emergent BioSolutions’s revenue streams?

Emergent BioSolutions's revenue streams in c 23 are Commercial Product, Product, Contracts and Grants, and Service. Commercial Product generated $497.3M in revenue, accounting 32.27% of the company's total revenue Product generated $944.5M in revenue, accounting 61.30% of the company's total revenue, down -2.25% year-over-year. Contracts and Grants generated $26.3M in revenue, accounting 1.71% of the company's total revenue, down -36.47% year-over-year. Service generated $72.8M in revenue, accounting 4.72% of the company's total revenue

What is Emergent BioSolutions’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Emergent BioSolutions was Product. This segment made a revenue of $944.5M, representing 61.30% of the company's total revenue.